+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Antibody Fragments Market by Type (F(ab) Fragments, F(ab')2 Fragments, Single Domain Antibody Fragments (sdAbs)), Antibody Type (Monoclonal, Polyclonal), Application - Forecast 2024-2030- Product Image
Global Antibody Fragments Market by Type (F(ab) Fragments, F(ab')2 Fragments, Single Domain Antibody Fragments (sdAbs)), Antibody Type (Monoclonal, Polyclonal), Application - Forecast 2024-2030- Product Image
Sale

Global Antibody Fragments Market by Type (F(ab) Fragments, F(ab')2 Fragments, Single Domain Antibody Fragments (sdAbs)), Antibody Type (Monoclonal, Polyclonal), Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5665739
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibody Fragments Market size was estimated at USD 7.72 billion in 2023, USD 8.07 billion in 2024, and is expected to grow at a CAGR of 4.36% to reach USD 10.42 billion by 2030.

Antibody fragments refer to parts of antibodies capable of binding to specific types of antigens, the foreign substances in the body that induce an immune response. Antibody fragments are usually derivatives from whole antibodies and are developed through enzyme digestion or genetic engineering techniques. The primary driver of this market development is the increasing adoption of targeted therapies for treating chronic conditions, such as autoimmune diseases. Advancements in genetic and biochemical technologies have also paved the way for enhanced production and engineering of these fragments, boosting growth.

A constant increase in R&D funding and robust healthcare infrastructure, especially in developed countries, contributed to overall market growth. However, the high costs of producing and purifying antibody fragments can restrict market growth. Regulatory challenges and lack of awareness in emerging markets also pose potential growth restrictions. New avenues for potential opportunities include the development of innovative drugs using antibody fragments and their usage in untapped disease areas. Additionally, the expansion and consolidation of pharmaceutical and biotechnological efforts in emerging markets also present significant opportunities for growth in the antibody fragments market.

Regional Insights

The Americas has a significant landscape in the antibody fragments market owing to ongoing research initiatives that pave the way for the market's growth. The purchasing behavior in these countries is predominantly driven by the advent of personalized medicine, with a notable focus on disease-specific applications. With the rising private and government entities' investments in next-generation healthcare technologies, further growth is anticipated. Europe, the Middle East, and Africa (EMEA) exhibit a burgeoning market for antibody fragments, driven by a rise in health consciousness and governmental initiatives for public health.

The increase in lifestyle diseases in these regions has necessitated innovative therapeutics in the healthcare sector. EU countries and the Middle East are experiencing heavy investments in diagnostic technologies and research, thus promising market potential. The Asia Pacific region, home to emerging healthcare influencers, is witnessing a growing demand for antibody fragments. Increased investments in research & development in the field indicate a promising market growth in this region. The customer behavior in this region reveals an inclination towards therapeutic applications, which many manufacturers are looking to capitalize on, further increasing the market growth in the area.

Market Trends by Segment

  • Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding
  • Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics
  • Application: Evolving application of antibody fragments in cancer therapy

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Lupin, Amman Pharma Collaborates for Exclusive Marketing of Ranibizumab

Lupin and Amman Pharma entered an exclusive marketing collaboration for Ranibizumab, a monoclonal antibody fragment. Ranibizumab is primarily used in the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). This strategic partnership will enhance Lupin's presence in the eye care sector in India and improve the accessibility of treatment for patients with wet AMD and DME.

Birmingham Platelet Group Delivers Breakthrough ‘nanobody’ Technology

The Birmingham Platelet Group has significantly advanced nanobody technology by creating antibody fragments. These fragments are smaller than conventional antibodies, allowing them to reach previously inaccessible areas in the body. This breakthrough has the potential to enhance treatment options for various diseases.

Attovia, a new California biotech, Launches with Plans to Rethink how Drugs Bind their Targets

Attovia introduced their groundbreaking Frazier-Alamar Nanobody, a distinctive antibody fragment composed of single variable domains derived from camelid heavy chain antibodies. This Nanobody is specifically engineered to exhibit exceptional affinity and stability, making it an ideal candidate for therapeutic applications across various indications.

Key Company Profiles

The report delves into recent significant developments in the Antibody Fragments Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Aenova Group GmbH, Almac Group, Amgen Inc., Antikor Biopharma, Astellas Pharma Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, Confo Therapeutics, Dyne Therapeutics, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilde Healthcare, Johnson & Johnson Services, Inc., MoonLake Immunotherapeutics AG, Novartis AG, Numab AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc.

This research report offers invaluable insights into various crucial aspects of the Antibody Fragments Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing use of antibody fragments in medical diagnostics
5.1.1.2. Rising incidences of various cancers and infectious diseases
5.1.1.3. Increasing number of drug discovery activities
5.1.2. Restraints
5.1.2.1. Strict regulatory guidelines for the approval of antibody fragments
5.1.3. Opportunities
5.1.3.1. Advancements in the clinical development of antibody fragments
5.1.3.2. Introduction of advanced recombinant DNA technology
5.1.4. Challenges
5.1.4.1. Insufficient efficacy and adverse effects in anticancer immunotherapy
5.2. Market Segmentation Analysis
5.2.1. Type: Burgeoning usage of single domain antibody fragments (sdAbs) in terms of applications due to their stability and flexibility in binding
5.2.2. Antibody Type: Proliferating utilization of monoclonal antibodies owing to their high specificity in targeted therapeutics
5.2.3. Application: Evolving application of antibody fragments in cancer therapy
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Antibody Fragments Market, by Type
6.1. Introduction
6.2. F(ab) Fragments
6.3. F(ab’)2 Fragments
6.4. Single Domain Antibody Fragments (sdAbs)
6.5. Single-chain Variable Fragments (scFvs)
7. Antibody Fragments Market, by Antibody Type
7.1. Introduction
7.2. Monoclonal
7.3. Polyclonal
8. Antibody Fragments Market, by Application
8.1. Introduction
8.2. Cancer
8.3. Immunodeficiencies
9. Americas Antibody Fragments Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Antibody Fragments Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Antibody Fragments Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Lupin, Amman Pharma Collaborates for Exclusive Marketing of Ranibizumab
12.3.2. Birmingham Platelet Group Delivers Breakthrough ‘nanobody’ Technology
12.3.3. Attovia, a new California biotech, Launches with Plans to Rethink how Drugs Bind their Targets
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. ANTIBODY FRAGMENTS MARKET RESEARCH PROCESS
FIGURE 2. ANTIBODY FRAGMENTS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTIBODY FRAGMENTS MARKET DYNAMICS
FIGURE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTIBODY FRAGMENTS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB) FRAGMENTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB’)2 FRAGMENTS, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY F(AB’)2 FRAGMENTS, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE DOMAIN ANTIBODY FRAGMENTS (SDABS), BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY SINGLE-CHAIN VARIABLE FRAGMENTS (SCFVS), BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY MONOCLONAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY POLYCLONAL, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY FRAGMENTS MARKET SIZE, BY IMMUNODEFICIENCIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 30. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 31. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 32. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 33. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 34. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 37. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 38. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 39. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 40. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 41. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 42. ARGENTINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 43. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 44. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 45. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 46. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 47. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 48. BRAZIL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 49. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 50. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 51. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 52. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 53. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 54. CANADA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 55. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 56. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 57. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 58. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 59. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 60. MEXICO ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 62. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 64. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 66. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES ANTIBODY FRAGMENTS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 70. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 72. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 74. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 77. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 78. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 79. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 80. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 81. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 82. AUSTRALIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 83. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 84. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 85. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 86. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 87. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 88. CHINA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 89. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 90. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 91. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 92. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 93. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 94. INDIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 95. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 96. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 97. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 98. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 99. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 100. INDONESIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 101. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 102. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 103. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 104. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 105. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 106. JAPAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 107. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 108. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 109. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 110. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 111. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 112. MALAYSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 113. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 114. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 115. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 116. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 117. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 118. PHILIPPINES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 119. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 120. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 121. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 122. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 123. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 124. SINGAPORE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 125. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 126. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 127. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 128. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 129. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 130. SOUTH KOREA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 131. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 132. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 133. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 134. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 135. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 136. TAIWAN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 137. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 138. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 139. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 140. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 141. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 142. THAILAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 143. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 144. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 145. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 146. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 147. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 148. VIETNAM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 157. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 158. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 159. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 160. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 161. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 162. DENMARK ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 163. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 164. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 165. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 166. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 167. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 168. EGYPT ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 169. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 170. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 171. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 172. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 173. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 174. FINLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 175. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 176. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 177. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 178. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 179. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 180. FRANCE ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 181. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 182. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 183. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 184. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 185. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 186. GERMANY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 187. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 188. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 189. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 190. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 191. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 192. ISRAEL ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 193. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 194. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 195. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 196. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 197. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 198. ITALY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 199. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 200. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 201. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 202. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 203. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 204. NETHERLANDS ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 205. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 206. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 207. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 208. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 209. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 210. NIGERIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 211. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 212. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 213. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 214. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 215. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 216. NORWAY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 217. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 218. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 219. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 220. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 221. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 222. POLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 223. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 224. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 225. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 226. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 227. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 228. QATAR ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 229. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 230. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 231. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 232. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 233. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 234. RUSSIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 236. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 238. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 240. SAUDI ARABIA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 242. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 244. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 246. SOUTH AFRICA ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 247. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 248. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 249. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 250. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 251. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 252. SPAIN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 253. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 254. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 255. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 256. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 257. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 258. SWEDEN ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 259. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 260. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 261. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 262. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 263. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 264. SWITZERLAND ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 265. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 266. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 267. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 268. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 269. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 270. TURKEY ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
TABLE 278. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2018-2023 (USD MILLION)
TABLE 280. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY ANTIBODY TYPE, 2024-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 282. UNITED KINGDOM ANTIBODY FRAGMENTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 283. ANTIBODY FRAGMENTS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 284. ANTIBODY FRAGMENTS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Aenova Group GmbH
  • Almac Group
  • Amgen Inc.
  • Antikor Biopharma
  • Astellas Pharma Inc.
  • Baxter International Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Confo Therapeutics
  • Dyne Therapeutics
  • Eli Lilly and Company
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Gilde Healthcare
  • Johnson & Johnson Services, Inc.
  • MoonLake Immunotherapeutics AG
  • Novartis AG
  • Numab AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 8.07 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.42 Billion
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Antibody Fragments Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Antibody Fragments Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 175 Pages
  • Global
From
Antibody Fragments Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Antibody Fragments Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 113 Pages
  • Global
From
2024 Global Forecast for Antibody Fragments (2025-2030 Outlook)-High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Antibody Fragments (2025-2030 Outlook)-High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From
Global Combination Antibody Therapy Market by Type (Antibody-Drug Conjugates, Bispecific Antibodies, Chemotherapy-Monoclonal Antibodies), Indication (Cancer, HIV), Route of Administration, Distribution Channel, End-Use - Forecast 2024-2030 - Product Image

Global Combination Antibody Therapy Market by Type (Antibody-Drug Conjugates, Bispecific Antibodies, Chemotherapy-Monoclonal Antibodies), Indication (Cancer, HIV), Route of Administration, Distribution Channel, End-Use - Forecast 2024-2030

  • Report
  • 188 Pages
  • Global
From
Global T-Cell Immunotherapy Market by Mechanism Of Action (Active Immunotherapy, Passive Immunotherapy), Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies), Type of Therapy, Indication - Forecast 2024-2030 - Product Image

Global T-Cell Immunotherapy Market by Mechanism Of Action (Active Immunotherapy, Passive Immunotherapy), Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies), Type of Therapy, Indication - Forecast 2024-2030

  • Report
  • 180 Pages
  • Global
From

About the Antibody Fragment Market

The Antibody Fragment market within the context of Oncology Drugs is a rapidly growing field of biotechnology. Antibody Fragments are small pieces of antibodies that are used to target and treat cancer cells. They are designed to bind to specific antigens on the surface of cancer cells, allowing them to be targeted and destroyed. Antibody Fragments are also used to deliver drugs directly to cancer cells, increasing the effectiveness of the drug. This technology has been used to develop a variety of cancer treatments, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. The Antibody Fragment market is expected to continue to grow as new treatments are developed and approved. This growth is driven by the increasing prevalence of cancer, as well as the need for more effective treatments. Some companies in the Antibody Fragment market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.